Biogen's 6-mg dose of its closely watched Alzheimer's drug aducanumab failed to deliver what the Big Biotech and anxious analysts were hoping to see, falling short of clinical significance on two key measures of efficacy that would have pointed toward a clear path ahead in a pivotal study.
Biogen and Eli Lilly, two drugmakers making big bets in Alzheimer's disease, are set to present clinical data on a pair of much-scrutinized projects with potential to change the industry's approach to the field.
The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.
Samsung Bioepis, a joint venture between the South Korean conglomerate and Biogen, is planning a jump to the Nasdaq with eyes on raising cash to market cheaper copies of blockbuster biologics.
Back in 2013, as Sangamo Biosciences negotiated what would become a sizable partnership deal, one of the company's officers leaked the news to a longtime friend, according to the SEC, setting in motion an insider trading scheme authorities say netted more than $1.2 million.
Hedge fund manager Kyle Bass has outlined how he picks pharma patents to challenge for his new money-spinning project. The project is underpinned by two emerging assets commonly thought of as a potential boon for drug developers: large data sets and algorithms with which to interrogate them.
Biogen's recent change back to its original name--from the decade-old merger name Biogen Idec--made sense in many ways. Along with the nod to its biotech founding heritage, most people already called the company simply "Biogen," anyway. But the switch to just Biogen also signaled a new direction for the company and recognized the new reality in pharma.
How much does it cost to develop a new drug? In Biogen's case, the answer is $2.5 billion. That's the figure that CEO George Scangos gave to the World Medical Innovation Forum in Boston for its much-hyped Alzheimer's drug, according to Bloomberg 's Michelle Fay Cortez.
Riding high on some promising Phase I data, Biogen has mapped out a big late-stage program for its Alzheimer's disease treatment, making a risky bet that it can reverse decades of failure in the field.
The wearable fitness trend has exploded in the past few years. But for patients with certain medical conditions, wearables are more than hipster status symbols. The devices could help them manage chronic conditions. And for pharma companies, they could gather data to help tailor new treatments, track patient outcomes, and develop relationships with the people who use their meds.